HomeAuthorsPosts by Sam Atkinson

Sam Atkinson

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge in profit for the third quarter ended May 31, 2026. This performance marks a decisive shift from a period of recovery toward a new phase of resilient growth in the...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the country grapples with a growing burden of non-communicable diseases (NCDs), particularly diabetes and chronic kidney disease. Recent estimates show that one-in-six Malaysians has diabetes, while one-in-seven is at risk of chronic...
spot_img

Keep exploring

SGX-LISTED COMPANIES

Offshore Wind & Shipyard Wins Transform Marco Polo Marine’s 1H FY2026

Full Steam Ahead For decades, the offshore maritime sector was defined by the volatile, boom-and-bust...
SGX-LISTED COMPANIES

Goodland Group 1H FY2026 Profits Surge Despite Falling Sales

Why a 29% Revenue Drop Led to a S$5.1 Million Comprehensive Profit Swing How can...
SGX-LISTED COMPANIES

Golden Agri-Resources Is Still Growing Despite Geopolitical Palm Oil Volatility – 1Q FY2026

The Agribusiness Paradox The global commodity markets of 2026 have been defined by a singular...
SGX-LISTED COMPANIES

OxPay’s 1Q FY2026 Sales Are Exploding, But There’s A Catch

Revenue Surges and Strategic Pivots The fintech sector is defined by its high-growth, high-risk nature...
SGX-LISTED COMPANIES

AJJ Medtech Moves Past Development Into Execution & Commercialization In 1Q 2026

From Platform to Profit In the arena of medical technology, the most hazardous terrain is...
SGX-LISTED COMPANIES

Why Singapore Airlines FY2025/26 Profit Dropped Despite Record Travel Demand

Deciphering SIA's $1.1 Billion Accounting Turbulence For the financial year ended 31 March 2026, Singapore...
SGX-LISTED COMPANIES

LHN Limited’s 1H FY2026 Profit Surge Showcases Exceptional Capital Efficiency

Less is More In equity research, we are conditioned to view top-line contraction as a...
SGX-LISTED COMPANIES

Katrina Faces Debt & Insolvency In Q1 FY2026 – Is The End Near?

A Tale of Two Segments and one Liquidity Tightrope For many Singaporeans, Katrina Group is...
SGX-LISTED COMPANIES

MTQ Corporation FY2026 Profits Vanish Amid Middle East Conflict

The Resilience of a 50-Year-Old Specialist MTQ Corporation, an engineering specialist with a pedigree stretching...
SGX-LISTED COMPANIES

Sinostar PEC’s Q1 2026 Results Are A Masterclass In Strategic Resilience

Middle East Tensions and Margin Magic In the discipline of equity research, we are conditioned...
SGX-LISTED COMPANIES

The Profit Growth Strategy Behind Kimly’s 1H FY2026

5 Strategic Takeaways from Kimly’s 1H FY2026 Results To many Singaporeans, Kimly is the ubiquitous...
SGX-LISTED COMPANIES

How BRC Asia Smashed Records In 1H FY2026 While Steel Prices Fell

The Steel Backbone of a Resurgent Sector Singapore’s construction landscape is entering a high-octane expansion...
Load more

Latest articles

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...
Pharmaceutical

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...
Pharmaceutical

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...